期刊文献+

静脉应用唑来膦酸注射液的临床安全性 被引量:4

Safety on intravenous use of zoledronic acid injection
在线阅读 下载PDF
导出
摘要 目的分析唑来膦酸注射液应用的安全性。方法采用回顾性研究方法,对我院2010年1月至2014年1月使用唑来膦酸注射液的710例患者的药物不良反应进行统计分析。结果唑来膦酸注射液的不良反应以发热最常见,发生率为95.07%,其次是低血钙、低血磷。全部不良反应均为一过性反应,无严重不良反应发生。结论唑来膦酸的不良反应发生率高,应积极给予退热治疗,并及时给予血钙、磷、钾、镁、铁、肌酐及血常规监测,以确保不良反应的平稳过渡。 Objective To analyze the safety of zoledronic acid injection in 710 patients.Methods The adverse reactions of patients who used zoledronic acid injection in our hospital from January 2010 to January 2014 were retrospectively analyzed.Results Fever was the most common adverse reaction of zoledronic acid injection,the incidence rate was 95.07%,followed by hypocalcemia,hypophosphatemia.All the adverse effects were transient response,no serious adverse reactions occurred.Conclusion The rate of adverse drug reaction of zoledronic acid was high,the antipyretic therapy should be given,and calcium,phosphorus,potassium,magnesium,iron,creatinine,blood routine monitoring should also be monitored in patients using zoledronic acid.
作者 赵淑慧
出处 《实用药物与临床》 CAS 2014年第12期1601-1603,共3页 Practical Pharmacy and Clinical Remedies
关键词 唑来膦酸注射液 不良反应 发热 Zoledronic acid injection Adverse reaction Fever
  • 相关文献

参考文献12

二级参考文献46

  • 1王志刚,姚杰,王洋,李鸣芳.卡培他滨对综合治疗失败的乳腺癌疗效观察[J].肿瘤防治研究,2007,34(7):528-529. 被引量:3
  • 2[1]Evdokiou A,Labrinidis A.Induction of cell death of human osteogenic sarcoma cells by zoledronic acid resembles anoikis[J].Bone,2003,33(2):216-28.
  • 3[2]Neville-Webbe H,Coleman RE.The use of zoledronic acid in the management of metastatic bone disease and hypercalcaemia[J].Palliat Med,2003,17(6):539-553.
  • 4[3]Witters LM,Crispino J.Effect of the combination of docetaxel,zoledronic acid,and a COX-2 inhibitor on the growth of human breast cancer cell lines[J].Am J Clin Oncol,2003,26(4):92-97.
  • 5[4]Jagdev SP,Croucher PI,Coleman RE.Zoledronate induces apoptosis of breast cancer cells in vitro evidence for additive and synergistic effects with taxol and tamoxifen[J].Proc Am Soc Clin Oncol,2000,19(6):664a.
  • 6[5]Tassone P,Forciniti S,Galea E,et al.Growth inhibition and synergistic induction of apoptosis by zoledronate and dexamethasone in human myeloma cell lines[J].Leukemia,2000,14(3):841-844.
  • 7[6]Chen T,Berenson J.Pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with bone metastases[J].J Clin Pharmacol,2002,42(11):1228-1236.
  • 8[7]Skerjance A,Berenson J.The pharmacokinetics and pharmacodynamics of zoledronic acid in cancer patients with varying degrees of renal function[J].J Clin Pharmacol,2003,43(2):154-162.
  • 9[8]Lipton A,Zheng M,Seaman J,et al.Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma[J].Cancer,2003,98(5):962-969.
  • 10[9]Smith MR,Eastham J,Gleason DM.Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer[J].J Urol,2003,169(6):2008-2012.

共引文献58

同被引文献37

引证文献4

二级引证文献19

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部